Consistently, IHC staining analysis of Ki-67 showed that SHCBP1 knockdown significantly enhanced trastuzumab suppression of cellular proliferation (Fig. 3j), underscoring that SHCBP1 depletion renders HER2-positive gastric cancer sensitive to trastuzumab both in vitro and in vivo. The gene discussed is ERBB2; the disease is gastric cancer.